Envoy Medical Signs Media Deal with New to The Street
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 02 2026
0mins
Envoy Medical has signed a multi-part national media series with New to The Street. The campaign is designed to increase awareness among investors, and the broader marketplace about the company's approach to hearing.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy COCH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on COCH
About COCH
Envoy Medical, Inc. is a hearing health company. The Company is engaged in providing medical technologies across the hearing loss spectrum, all designed to shift the paradigm within the hearing industry and bring both providers and patients the hearing devices they require. Its hearing solutions include hearing aids, middle ear implants, bone conduction devices and cochlear implants. The bone conduction hearing device has two components: an external component and a surgically implanted fixture placed in the bone behind the ear. Its bone conduction hearing device offers amplification without ear mold in the ear. Its hearing aids are devices that amplify sound for those with mild to moderate hearing loss. Its Esteem is a fully implanted active middle ear implant designed to improve the hearing of adults diagnosed with moderate to severe sensorineural hearing loss. Cochlear implants are a solution for people with moderate-to-profound sensorineural hearing loss.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Envoy Medical Reports FY 2025 Financial Results
- Financial Overview: Envoy Medical's FY 2025 GAAP EPS stands at -$1.23 with revenue of only $0.02M, indicating significant challenges in revenue growth that may impact investor confidence.
- Sales and Marketing Expenses: As of December 31, 2025, sales and marketing expenses were $1,220, down $514 from $1,734 in 2024, primarily due to reduced legal fees associated with the Esteem FI-AMEI product, reflecting the company's efforts in cost control.
- Rising Administrative Costs: General and administrative expenses increased to $7,931 in FY 2025 from $6,826 in 2024, up $1,105 mainly due to severance costs for the former CFO and increased consulting expenses, indicating financial pressure amid management changes.
- Cash Position: As of December 31, 2025, Envoy Medical had approximately $3.7 million in cash, which, while adequate, may limit operational flexibility given the ongoing losses.
See More
Envoy Medical Regains Nasdaq Compliance
- Compliance Notification: Envoy Medical announced it has received a notice from Nasdaq confirming its regained compliance under Rule 5550(b) through permitted alternatives, indicating an improvement in the company's market value compliance.
- Market Value Issue: The company previously received a Nasdaq notice on February 25, 2025, for failing to meet the minimum $35 million market value requirement for listed securities, highlighting challenges in maintaining its market position.
- Confidence in Compliance Plan: Envoy Medical stated it believes it has developed an achievable plan to maintain compliance, which is expected to bolster investor confidence in the company's future prospects.
- Funding Initiative: The company also announced a public offering of up to $78 million, which is anticipated to further strengthen its capital base and support future business expansion.
See More
Envoy Medical Prices Upsized Public Offering of 75M Shares
- Offering Size: Envoy Medical announced an upsized public offering of 75 million shares of Class A common stock, along with Series A-1 and A-2 common warrants, priced at $0.40 per share, which is expected to generate approximately $30 million in gross proceeds, enhancing liquidity for future growth initiatives.
- Warrant Details: The Series A-1 warrants have an exercise price of $0.40 per share and will become exercisable upon stockholder approval, expiring 24 months later, while the Series A-2 warrants, also priced at $0.40, will be exercisable for 60 months, reflecting the company's confidence in future FDA approvals.
- Use of Proceeds: Envoy Medical intends to utilize the net proceeds from the offering for working capital and other general corporate purposes, particularly to fund its FDA pivotal clinical study, thereby advancing the commercialization of its Acclaim cochlear implant.
- Market Reaction: Despite a 2.51% decline in COCH's stock price to $0.3801 following the offering announcement, the potential additional gross proceeds from the warrants could reach $48 million, indicating the company's strategic positioning and fundraising capabilities for future developments.
See More
Highlights from the Small Cap Growth Virtual Investor Conference
- On-Demand Viewing: Presentations from the Small Cap Growth Virtual Investor Conference held on February 5, 2026, are now available for on-demand viewing for 90 days, enhancing investor engagement and understanding of participating companies.
- 1x1 Meeting Requests: Selected companies are accepting one-on-one management meeting requests until February 10, providing investors with direct access to executives, which could facilitate informed investment decisions and potential capital inflows.
- Diverse Company Participation: The conference featured presentations from various companies, including Betolar Oyj, Envoy Medical Inc., and C-COM Satellite Systems Inc., showcasing a wide range of investment opportunities in the small-cap growth sector, attracting diverse investor interest.
- Advantages of Virtual Conferences: Virtual Investor Conferences offer a real-time interactive platform that enhances connections between companies and investors, improving the investor experience and creating more efficient fundraising and marketing opportunities for participating firms.
See More
Highlights from the Small Cap Growth Virtual Investor Conference
- On-Demand Content: Presentations from the Small Cap Growth Virtual Investor Conference held on February 5, 2026, are now available for on-demand viewing, allowing investors to access content 24/7 for 90 days, thereby increasing attention on small-cap growth companies.
- Investor Participation: The conference invites individual and institutional investors, advisors, and analysts to participate, providing an interactive platform that facilitates direct communication between investors and companies, enhancing investor relations management.
- One-on-One Meeting Opportunities: Selected companies are accepting one-on-one management meeting requests until February 10, offering investors a chance to engage directly with company executives, which deepens investor engagement and trust.
- Advantages of Virtual Conferences: Virtual Investor Conferences replicate the components of on-site investor meetings through real-time investor engagement solutions, enhancing the efficiency of connections between companies and investors and modernizing investor communications.
See More
Agenda Released for Small Cap Growth Virtual Investor Conference
- Conference Schedule: The Small Cap Growth Virtual Investor Conference is set for February 5, featuring a diverse lineup of innovative companies, aimed at providing investors direct access to the small-cap market, thereby enhancing interaction and engagement with companies.
- Participant Invitation: The conference invites individual investors, institutional investors, advisors, and analysts to attend at no cost, aiming to streamline the registration process and system checks to enhance participation efficiency and ensure timely updates for investors.
- Company Showcase Opportunity: Jason Paltrowitz, Executive Vice President at OTC Markets Group, emphasized that the conference will highlight a diverse roster of companies, showcasing innovation in the small-cap market and helping firms effectively communicate their growth narratives to bolster investor confidence.
- Investor Relations Facilitation: Virtual Investor Conferences provide a real-time investor engagement solution, allowing companies to communicate directly with a global investor audience, schedule one-on-one meetings, and enhance presentation effectiveness, thus accelerating the next phase of investor participation.
See More
Envoy Medical Reports FY 2025 Financial Results
- Financial Overview: Envoy Medical's FY 2025 GAAP EPS stands at -$1.23 with revenue of only $0.02M, indicating significant challenges in revenue growth that may impact investor confidence.
- Sales and Marketing Expenses: As of December 31, 2025, sales and marketing expenses were $1,220, down $514 from $1,734 in 2024, primarily due to reduced legal fees associated with the Esteem FI-AMEI product, reflecting the company's efforts in cost control.
- Rising Administrative Costs: General and administrative expenses increased to $7,931 in FY 2025 from $6,826 in 2024, up $1,105 mainly due to severance costs for the former CFO and increased consulting expenses, indicating financial pressure amid management changes.
- Cash Position: As of December 31, 2025, Envoy Medical had approximately $3.7 million in cash, which, while adequate, may limit operational flexibility given the ongoing losses.
See More
Envoy Medical Regains Nasdaq Compliance
- Compliance Notification: Envoy Medical announced it has received a notice from Nasdaq confirming its regained compliance under Rule 5550(b) through permitted alternatives, indicating an improvement in the company's market value compliance.
- Market Value Issue: The company previously received a Nasdaq notice on February 25, 2025, for failing to meet the minimum $35 million market value requirement for listed securities, highlighting challenges in maintaining its market position.
- Confidence in Compliance Plan: Envoy Medical stated it believes it has developed an achievable plan to maintain compliance, which is expected to bolster investor confidence in the company's future prospects.
- Funding Initiative: The company also announced a public offering of up to $78 million, which is anticipated to further strengthen its capital base and support future business expansion.
See More
Envoy Medical Prices Upsized Public Offering of 75M Shares
- Offering Size: Envoy Medical announced an upsized public offering of 75 million shares of Class A common stock, along with Series A-1 and A-2 common warrants, priced at $0.40 per share, which is expected to generate approximately $30 million in gross proceeds, enhancing liquidity for future growth initiatives.
- Warrant Details: The Series A-1 warrants have an exercise price of $0.40 per share and will become exercisable upon stockholder approval, expiring 24 months later, while the Series A-2 warrants, also priced at $0.40, will be exercisable for 60 months, reflecting the company's confidence in future FDA approvals.
- Use of Proceeds: Envoy Medical intends to utilize the net proceeds from the offering for working capital and other general corporate purposes, particularly to fund its FDA pivotal clinical study, thereby advancing the commercialization of its Acclaim cochlear implant.
- Market Reaction: Despite a 2.51% decline in COCH's stock price to $0.3801 following the offering announcement, the potential additional gross proceeds from the warrants could reach $48 million, indicating the company's strategic positioning and fundraising capabilities for future developments.
See More
Highlights from the Small Cap Growth Virtual Investor Conference
- On-Demand Viewing: Presentations from the Small Cap Growth Virtual Investor Conference held on February 5, 2026, are now available for on-demand viewing for 90 days, enhancing investor engagement and understanding of participating companies.
- 1x1 Meeting Requests: Selected companies are accepting one-on-one management meeting requests until February 10, providing investors with direct access to executives, which could facilitate informed investment decisions and potential capital inflows.
- Diverse Company Participation: The conference featured presentations from various companies, including Betolar Oyj, Envoy Medical Inc., and C-COM Satellite Systems Inc., showcasing a wide range of investment opportunities in the small-cap growth sector, attracting diverse investor interest.
- Advantages of Virtual Conferences: Virtual Investor Conferences offer a real-time interactive platform that enhances connections between companies and investors, improving the investor experience and creating more efficient fundraising and marketing opportunities for participating firms.
See More
Highlights from the Small Cap Growth Virtual Investor Conference
- On-Demand Content: Presentations from the Small Cap Growth Virtual Investor Conference held on February 5, 2026, are now available for on-demand viewing, allowing investors to access content 24/7 for 90 days, thereby increasing attention on small-cap growth companies.
- Investor Participation: The conference invites individual and institutional investors, advisors, and analysts to participate, providing an interactive platform that facilitates direct communication between investors and companies, enhancing investor relations management.
- One-on-One Meeting Opportunities: Selected companies are accepting one-on-one management meeting requests until February 10, offering investors a chance to engage directly with company executives, which deepens investor engagement and trust.
- Advantages of Virtual Conferences: Virtual Investor Conferences replicate the components of on-site investor meetings through real-time investor engagement solutions, enhancing the efficiency of connections between companies and investors and modernizing investor communications.
See More
Agenda Released for Small Cap Growth Virtual Investor Conference
- Conference Schedule: The Small Cap Growth Virtual Investor Conference is set for February 5, featuring a diverse lineup of innovative companies, aimed at providing investors direct access to the small-cap market, thereby enhancing interaction and engagement with companies.
- Participant Invitation: The conference invites individual investors, institutional investors, advisors, and analysts to attend at no cost, aiming to streamline the registration process and system checks to enhance participation efficiency and ensure timely updates for investors.
- Company Showcase Opportunity: Jason Paltrowitz, Executive Vice President at OTC Markets Group, emphasized that the conference will highlight a diverse roster of companies, showcasing innovation in the small-cap market and helping firms effectively communicate their growth narratives to bolster investor confidence.
- Investor Relations Facilitation: Virtual Investor Conferences provide a real-time investor engagement solution, allowing companies to communicate directly with a global investor audience, schedule one-on-one meetings, and enhance presentation effectiveness, thus accelerating the next phase of investor participation.
See More
